BioCentury
ARTICLE | Clinical News

Relvar Ellipta regulatory update

December 12, 2016 10:30 PM UTC

GlaxoSmithKline and Innoviva (formerly Theravance Inc.) said Japan approved an expanded label for Relvar Ellipta fluticasone furoate/vilanterol to include treatment of chronic obstructive pulmonary disease (COPD) when concurrent use of an inhaled corticosteroid and an inhaled long-acting adrenergic receptor beta 2 agonist (LABA) is required. Relvar Ellipta is already approved in Japan for asthma. Fluticasone furoate/vilanterol is approved for COPD and asthma as Breo Ellipta in the U.S. and as Relvar Ellipta in Europe. The product is a fixed-dose combination of the inhaled corticosteroid fluticasone furoate and the LABA vilanterol administered with the dry powder Ellipta inhaler...

BCIQ Company Profiles

GSK plc

Innoviva Inc.

BCIQ Target Profiles

Adrenergic receptor beta 2